Galderma Laboratories has awarded agency of record for advertising and promotion for three products in the corrective and aesthetic market to Brand Pharm, a member of the Publicis Healthcare Communications Group of agencies. Two of the products – Pliaglistm (7% lidocaine/7 % tetracaine), a topical anesthetic, and Elevesstm, a cosmetic filler - are new products. The third product – Tri-Luma (fluocinolone acetonide 0.01%, hydroquinone 4%, tretinoin 0.05%), a treatment for melasma, a hyperpigmentation disorder - was already a Brand Pharm assignment for medical promotions. These new assignments increase the total to five products the agency's assignments with Galderma. Brand Pharm has had the agency assignment for Differin (adapalene), a prescription treatment for acne, and Metrogel (metronidazole gel, 1%), one of the leading therapies prescribed by dermatologists for rosacea.